PapersFlow Research Brief
Pharmacology and Obesity Treatment
Research Guide
What is Pharmacology and Obesity Treatment?
Pharmacology and obesity treatment is the study of pharmacological agents and their clinical evaluation for managing obesity, including drugs such as sibutramine, orlistat, and ephedra alkaloids, alongside assessments of efficacy, safety, weight loss outcomes, and associated adverse events.
This field encompasses 54,527 papers on anti-obesity drugs and clinical trials evaluating their impact on weight loss. Key medications include lipase inhibitors like orlistat, alongside sibutramine and ephedra alkaloids. Research addresses both therapeutic benefits and adverse events in obesity pharmacotherapy.
Topic Hierarchy
Research Sub-Topics
Sibutramine Efficacy and Safety in Obesity Trials
This sub-topic evaluates sibutramine's appetite suppression via serotonin and norepinephrine reuptake inhibition in randomized controlled trials. Researchers analyze cardiovascular risks and long-term weight maintenance outcomes.
Orlistat as Lipase Inhibitor for Weight Management
This sub-topic examines orlistat's pancreatic lipase blockade reducing fat absorption in clinical settings. Researchers study gastrointestinal side effects and comparative efficacy with lifestyle interventions.
Ephedra Alkaloids in Obesity Pharmacotherapy
This sub-topic investigates ephedrine and pseudoephedrine's thermogenic and sympathomimetic effects on energy expenditure. Researchers assess adverse events like hypertension leading to market bans.
Adverse Events of Anti-Obesity Medications
This sub-topic profiles safety concerns including psychiatric, cardiovascular, and hepatotoxic effects across drug classes. Researchers use pharmacoepidemiology to quantify post-marketing risks.
Clinical Trial Design for Anti-Obesity Drugs
This sub-topic covers endpoints, durations, and surrogate markers in phase II/III trials for novel agents. Researchers debate FDA criteria like 5% weight loss thresholds and composite outcomes.
Why It Matters
Pharmacological interventions target obesity-related conditions like type 2 diabetes and cardiovascular risks, with clinical trials showing metformin reduces diabetes incidence by 31% in high-risk individuals compared to placebo, as demonstrated in "Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin" by William C. Knowler (2002). The "2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults" by Michael D. Jensen et al. (2013) provides evidence-based recommendations for obesity management, integrating pharmacotherapy with lifestyle changes to lower risks of myocardial infarction, stroke, and renal failure. In overweight type 2 diabetes patients, intensive glucose control with metformin decreased complications, positioning it as a first-line therapy with less weight gain than insulin or sulphonylureas, per "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)" (1998). These approaches address the metabolic syndrome, a cluster of risk factors including dyslipidemia and hypertension outlined in "Harmonizing the Metabolic Syndrome" by K. G. M. M. Alberti et al. (2009).
Reading Guide
Where to Start
"Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin" by William C. Knowler (2002), as it provides foundational evidence on metformin's role in high-risk obesity patients and compares it directly to lifestyle interventions.
Key Papers Explained
"Harmonizing the Metabolic Syndrome" by K. G. M. M. Alberti et al. (2009) establishes risk factor clusters relevant to obesity pharmacotherapy, which "Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin" by William C. Knowler (2002) builds on by showing metformin's diabetes prevention in those at risk. "Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance" by Jaakko Tuomilehto et al. (2001) complements this with lifestyle data, while "2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults" by Michael D. Jensen et al. (2013) synthesizes these into management guidelines incorporating drugs like metformin. UKPDS papers, such as "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)" (1998), extend findings to complication reduction.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues to emphasize metabolic syndrome harmonization and diabetes prevention in obesity contexts, as seen in top-cited works up to 2013, with integration into hypertension and overweight guidelines. No recent preprints or news alter these directions.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Reduction in the Incidence of Type 2 Diabetes with Lifestyle I... | 2002 | New England Journal of... | 18.7K | ✓ |
| 2 | Harmonizing the Metabolic Syndrome | 2009 | Circulation | 14.2K | ✓ |
| 3 | Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle... | 2001 | New England Journal of... | 10.8K | ✓ |
| 4 | Intensive blood-glucose control with sulphonylureas or insulin... | 1998 | The Lancet | 8.4K | ✕ |
| 5 | Effect of intensive blood-glucose control with metformin on co... | 1998 | The Lancet | 8.2K | ✕ |
| 6 | 2014 Evidence-Based Guideline for the Management of High Blood... | 2013 | JAMA | 7.9K | ✕ |
| 7 | Tight blood pressure control and risk of macrovascular and mic... | 1998 | BMJ | 6.7K | ✓ |
| 8 | Tight blood pressure control and risk of macrovascular and mic... | 1998 | — | 4.8K | ✕ |
| 9 | Effect of intensive blood-glucose control with metformin on co... | 1998 | PubMed | 4.3K | ✕ |
| 10 | 2013 AHA/ACC/TOS Guideline for the Management of Overweight an... | 2013 | Journal of the America... | 4.0K | ✓ |
Frequently Asked Questions
What drugs are central to obesity pharmacotherapy?
Key medications include sibutramine, orlistat, ephedra alkaloids, and lipase inhibitors. These agents are evaluated in clinical trials for weight loss efficacy and safety. Metformin also plays a role in managing obesity-related diabetes.
How does metformin impact obesity treatment?
"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)" (1998) shows metformin reduces diabetes-related endpoints in overweight patients. It causes less weight gain and fewer hypoglycemic attacks than insulin or sulphonylureas. This supports its use as first-line pharmacological therapy.
What is the scope of clinical trials in this field?
Trials assess anti-obesity drugs for efficacy, safety, weight loss, and adverse events. "Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin" by William C. Knowler (2002) compared metformin to lifestyle intervention in high-risk persons. Outcomes include reduced diabetes incidence.
What risks does the metabolic syndrome pose in obesity pharmacology?
"Harmonizing the Metabolic Syndrome" by K. G. M. M. Alberti et al. (2009) defines it as a cluster of cardiovascular and diabetes risk factors like raised blood pressure and dyslipidemia. Pharmacotherapy targets these to prevent complications. It occurs more frequently than by chance.
What guidelines exist for obesity management?
"2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults" by Michael D. Jensen et al. (2013) offers evidence-based strategies. It integrates pharmacotherapy for adults. The focus is on reducing disease burden from overweight conditions.
How does pharmacotherapy prevent type 2 diabetes?
"Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin" by William C. Knowler (2002) found lifestyle intervention and metformin both lowered incidence in high-risk persons. Lifestyle was more effective than metformin. Changes in subjects with impaired glucose tolerance also prevent diabetes, per Jaakko Tuomilehto et al. (2001).
Open Research Questions
- ? How can pharmacotherapies like orlistat and sibutramine be optimized to maximize weight loss while minimizing adverse events?
- ? What are the long-term cardiovascular outcomes of anti-obesity drugs in patients with metabolic syndrome?
- ? In what ways do lipase inhibitors interact with gut microbiota to influence obesity treatment efficacy?
- ? How do ephedra alkaloids compare to newer agents in preventing type 2 diabetes progression?
- ? What personalized dosing strategies improve safety profiles of sibutramine in diverse populations?
Recent Trends
The field maintains 54,527 works with focus on anti-obesity drugs like sibutramine, orlistat, and ephedra alkaloids, but no growth rate data or recent preprints/news available.
Top citations remain dominated by diabetes prevention studies, such as William C. Knowler with 18,734 citations and K. G. M. M. Alberti et al. (2009) with 14,222 citations.
2002Research Pharmacology and Obesity Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pharmacology and Obesity Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers